Aligos Therapeutics Correlations

ALGS Stock

USD 30.82 3.26 11.83%

The current 90-days correlation between Aligos Therapeutics and CytomX Therapeutics is -0.1 (i.e., Good diversification). The correlation of Aligos Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.

Aligos Therapeutics Correlation With Market

Good diversification

The correlation between Aligos Therapeutics and DJI is -0.04 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Aligos Therapeutics and DJI in the same portfolio, assuming nothing else is changed.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aligos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Aligos Stock please use our How to Invest in Aligos Therapeutics guide.

Moving together with Aligos Stock

0.8	DYAI	Dyadic International	Pair Corr
0.79	ESPR	Esperion Therapeutics	Pair Corr
0.66	BMY	Bristol Myers Squibb	Pair Corr
0.68	MNMD	Mind Medicine	Pair Corr
0.61	ABCL	Abcellera Biologics	Pair Corr

Moving against Aligos Stock

0.82	GNFT	Genfit	Pair Corr
0.76	PFE	Pfizer Inc Fiscal Year End 4th of February 2025	Pair Corr
0.75	VALN	Valneva SE ADR	Pair Corr
0.7	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr
0.68	ERNA	Eterna Therapeutics	Pair Corr
0.67	IMAB	I Mab	Pair Corr
0.64	LLY	Eli Lilly	Pair Corr
0.49	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.39	INBX	Inhibrx Symbol Change	Pair Corr
0.32	SLS	Sellas Life Sciences	Pair Corr
0.83	AMGN	Amgen Inc	Pair Corr
0.71	MRVI	Maravai Lifesciences Buyout Trend	Pair Corr
0.68	ABBV	AbbVie Inc	Pair Corr
0.61	REGN	Regeneron Pharmaceuticals	Pair Corr
0.56	SXTPW	60 Degrees Pharmaceu	Pair Corr
0.55	RANI	Rani Therapeutics	Pair Corr
0.49	MBIO	Mustang Bio	Pair Corr
0.49	AKAN	Akanda Corp	Pair Corr
0.46	ABOS	Acumen Pharmaceuticals	Pair Corr
0.42	ALVO	Alvotech	Pair Corr
0.41	NUVL	Nuvalent	Pair Corr
0.85	TFFP	Tff Pharmaceuticals	Pair Corr
0.73	APGE	Apogee Therapeutics,	Pair Corr
0.7	AVDL	Avadel Pharmaceuticals	Pair Corr
0.62	AQST	Aquestive Therapeutics	Pair Corr
0.6	TCRX	Tscan Therapeutics	Pair Corr
0.59	BCDA	Biocardia	Pair Corr

Related Correlations Analysis

	CTMX	SPRO	NLTX	TIL	NXTC	ASMB	ACHL	NUVB
CTMX		0.37	0.16	0.46	0.09	0.26	-0.55	0.18	CTMX
SPRO	0.37		0.25	0.54	0.72	0.32	-0.61	0.0	SPRO
NLTX	0.16	0.25		0.55	0.35	-0.12	-0.22	-0.06	NLTX
TIL	0.46	0.54	0.55		0.45	0.12	-0.41	-0.02	TIL
NXTC	0.09	0.72	0.35	0.45		0.3	-0.39	-0.25	NXTC
ASMB	0.26	0.32	-0.12	0.12	0.3		-0.42	0.3	ASMB
ACHL	-0.55	-0.61	-0.22	-0.41	-0.39	-0.42		-0.35	ACHL
NUVB	0.18	0.0	-0.06	-0.02	-0.25	0.3	-0.35		NUVB
	CTMX	SPRO	NLTX	TIL	NXTC	ASMB	ACHL	NUVB

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

Correlation Matchups

Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.

High positive correlations

NXTC	+ 0.72	SPRO
TIL	+ 0.55	NLTX
TIL	+ 0.54	SPRO
TIL	+ 0.46	CTMX
NXTC	+ 0.45	TIL
SPRO	+ 0.37	CTMX

High negative correlations

ACHL	- 0.61	SPRO
ACHL	- 0.55	CTMX
ACHL	- 0.42	ASMB
ACHL	- 0.41	TIL
ACHL	- 0.39	NXTC
NUVB	- 0.35	ACHL

Risk-Adjusted Indicators

There is a big difference between Aligos Stock performing well and Aligos Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Aligos Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
CTMX	2.96	(0.10)	(0.03)	0.02	3.33	(3.93)	6.78	(5.22)	22.92
SPRO	1.79	(0.27)	0.00	(0.68)	0.00	0.00	3.45	(4.58)	14.92
NLTX	2.25	(0.19)	0.00	(2.19)	0.00	0.00	4.05	(3.53)	27.84
TIL	8.69	0.60	0.11	0.28	7.65	(11.22)	16.79	(10.89)	105.83
NXTC	2.67	(0.26)	0.00	(62.99)	0.00	0.00	5.22	(5.52)	21.68
ASMB	2.85	(0.02)	(0.02)	0.07	4.31	(2.81)	8.79	(5.34)	21.34
ACHL	1.93	0.47	0.22	0.42	1.37	(3.10)	3.06	(2.80)	38.16
NUVB	3.43	(0.47)	0.00	(0.01)	0.00	0.00	9.48	(8.36)	21.30

Aligos Therapeutics Corporate Management

TseI Lin	VP Head	Profile
Leonid Beigelman	Pres Director	Profile
Dr DABT	Executive Sciences	Profile
Kristina Engeseth	Ex Culture	Profile
Lucinda JD	Chief VP	Profile
John Fry	Ex Devel	Profile

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC